Roche has announced it has received FDA clearance for a blood glucose monitor for hospital point-of-care testing, according to a news release.
The ACCU-CHEK Inform II system is described as a wireless hospital blood glucose device that enables automatic real-time wireless transfer of patient data between hospital medical staff and the laboratory.
"Accuracy and patient safety are the foremost concerns for blood glucose testing in hospitals and other point-of-care settings," said Roland Diggelmann, chief operating officer at Roche Diagnostics, in the release. "ACCU-CHEK systems have been proven in hospitals around the world and this next-generation wireless system sets a new standard by offering U.S. healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care."
The system is expected to be available in the United States beginning this month.
Roche is headquartered in Basel, Switzerland.
Related Articles on FDA Clearances:
ThromboGenics Receives FDA Approval for Symptomatic Vitreomacular Adhesion Drug
Edwards Lifesciences Receives FDA Expanded Approval for Artificial Heart Valve
Loma Vista Medical Receives FDA Clearance for Balloon Valvuloplasty Catheter